TrippBio has announced positive interim data from the investigator-initiated study (IIS) to assess the efficacy of TD213 in treating patients with confirmed mild-moderate COVD-19. The study was conducted by Dr. Moti N. Ramgopal of Midway Immunology and Research Center. Outpatients who tested positive using a validated SARS-CoV-2 RNA COVID-19 test were given TD213 twice daily for 14 days and will be followed through day 28.
After 14 days, 90% of enrolled patients receiving TD213 had cleared the virus.
“I was very pleased to see that 20% of the patients cleared by day five, and 40% by day ten, as well as the 14-day clearance data. Especially, when compared to the median time of 17.2 days to stop viral shedding reported in a mild-moderate population in a recently published review of 77 studies looking at COVID-19 patients,” Dr. Ramgopal, the principal investigator, said.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox! Sign up now!
An initial review of laboratory tests showed that a critical marker of inflammation, high-sensitive C-reactive protein (hsCRP), improved after four days of treatment in 60% of patients and 90% of patients after 14 days of treatment.
"We're thankful to the staff at Midway for conducting this study. This data will be an important component of our discussions with the FDA as we pursue our plan to rapidly move into confirmatory studies designed to gain approval of TD213 for the treatment of non-hospitalized patients with mild to moderate infections," Philip Young, CEO, said.